US 11421034
Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
granted A61KA61K2039/507A61K2039/545
Quick answer
US patent 11421034 (Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer) held by Five Prime Therapeutics, Inc. expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K2039/507, A61K2039/545, A61K2039/57, A61K2300/00